Effect of laftidine on Helicobacter pylori test: crossover comaparison with proton pump inhibitor

Effect of laftidine on Helicobacter pylori test: crossover comaparison with proton pump inhibitor - Effect of laftidine on Helicobacter pylori

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003467

Enrollment

Registered

2010-07-01

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health adult volunteer with Hp infection

Interventions

Laftidine 10mg twice daily for 14 days Lansoprazole 30mg once daily for 14 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy adult volunteer with Hp infection

Exclusion criteria

Exclusion criteria: 1) Subjects with hyper sensitivity for laftidine pr lansoprazole 2) Subjects who are taking Atazanavir Sulfate 3) Subjects with hepatic or renal failure , or subjects under renal hemodialysis 4) Subjects older than 65 5) subjects with history of digestive tract resection or vagotomy 6) Subjects who were taking H2-blocker or PPI within 2 weeks 7) Subjects with serious disease such as neoplasm 8) Pregnant, parturient and/or lactating women having a potential of pregnancy 9) Subjects with hyper sensitivity for any druds 10) Subjects who were considered ineligible by the investigator for other reasons

Design outcomes

Primary

Measure	Time frame
Influence on test results of Hp	—

Countries

Japan

Contacts

Public ContactMasanori Ito

Hiroshima University Hospital Department of Gastroenterology and Metabolism

maito@hiroshima-u.ac.jp+81-82-257-5191

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026